Proposal for MCC950

Overview of Therapeutic Candidate
MCC950 is a fully synthetic, small‐molecule inhibitor that was discovered using high‐throughput screening methods followed by extensive medicinal chemistry optimization. Initially identified as a potent inhibitor of IL-1β processing, MCC950 belongs to the diarylsulfonylurea class of compounds whose chemical frameworks were originally developed in contexts such as anti-diabetic research and have been later repurposed for controlling inflammasome-driven inflammation. Its chemical structure is defined by a hexahydroindacene tricyclic ring system that is fused to a sulfonylurea pharmacophore, with additional heteroaromatic substituents added to optimize crucial pharmacokinetic properties such as oral bioavailability and central nervous system penetration. The synthesis of MCC950 involved derivatization of sulfonamide intermediates, ensuring that the final molecule attained both the necessary lipophilicity for membrane permeability and the polar interactions required for high-affinity binding to its molecular target (Agarwal et al., 2020; Coll et al., 2015). In recent studies, related sulfonylurea compounds have been further optimized to address issues such as hepatotoxicity and systemic off-target effects by modifying key structural motifs; these efforts underscore the importance of the diarylsulfonylurea scaffold as a promising chemical class for modulating inflammatory pathways through direct inhibition of the NLRP3 inflammasome (Bertinaria et al., 2019; Jiang et al., 2019). Overall, MCC950 stands out among other NLRP3 inhibitors because it combines a well-defined molecular structure with excellent drug-like properties, positioning it as a leading candidate to be repurposed for chronic inflammatory conditions such as Age-Related Hearing Loss (ARHL).

Therapeutic History
Historically, MCC950 has been employed primarily as a research tool to elucidate the role of the NLRP3 inflammasome in a variety of inflammatory, autoimmune, and neurodegenerative disease models. Extensive preclinical studies in rodent models have shown that MCC950 potently inhibits inflammasome assembly in mouse bone marrow-derived macrophages, human peripheral blood mononuclear cells, and other immune cell types at low nanomolar concentrations. It has demonstrated efficacy in mitigating disease phenotypes in models of experimental autoimmune encephalomyelitis, cryopyrin-associated periodic syndromes (CAPS), and even in paradigms mimicking neuroinflammatory conditions such as traumatic brain injury and Alzheimer’s disease (Coll et al., 2015; Coll et al., 2019). In one notable preclinical study, MCC950 was able to reduce the release of inflammatory cytokines and suppress downstream NF-κB signaling, thereby reducing tissue damage and improving clinical outcomes in animal models of stroke and other inflammatory conditions (Perera et al., 2018; Wu et al., 2020). Despite robust preclinical efficacy, MCC950’s clinical development encountered challenges when dose-dependent liver enzyme elevations were observed during a phase II clinical trial in rheumatoid arthritis patients. This safety concern led to the discontinuation of further clinical development in that indication, although the compound continues to serve as a gold-standard research probe for exploring the biology of the NLRP3 inflammasome. Importantly, while MCC950 has been extensively characterized in inflammatory and neurodegenerative contexts, there is currently no direct evidence from the literature that it has been tested or validated in models of Age-Related Hearing Loss or cochlear inflammation. Yet, the mechanistic parallels between NLRP3-driven inflammation in other tissues and the emerging role of inflammasome activity in age-related cochlear degeneration suggest that repurposing MCC950 for ARHL holds significant promise (Bai et al., 2021; Bazard et al., 2021).

Mechanism of Action
At its core, MCC950 operates through a highly selective inhibition of the NLRP3 inflammasome, a multiprotein complex that is a central regulator of the innate immune response. Biochemically, the compound exerts its action by directly binding to the NACHT domain of the NLRP3 protein. More specifically, MCC950 targets the Walker B motif within this domain, thereby directly blocking ATP hydrolysis. This step is critical because ATP hydrolysis is required for the conformational changes that yield NLRP3 oligomerization and subsequent assembly of the inflammasome complex. Inhibition of ATP hydrolysis by MCC950 effectively stabilizes NLRP3 in its inactive, closed conformation, precluding the recruitment of the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) and the subsequent activation of caspase-1 (Coll et al., 2019). As a result, the proteolytic processing of pro-inflammatory cytokines such as IL-1β and IL-18 is halted. These cytokines are normally generated through caspase-1 mediated cleavage and are responsible for propagating robust inflammatory signaling cascades, including the activation of the transcription factor NF-κB. Of particular importance is that MCC950 demonstrates specificity by not affecting upstream priming signals such as Toll-like receptor (TLR)-mediated NF-κB activation or interfering with other inflammasome complexes like AIM2 or NLRC4. This ensures that the compound specifically negates NLRP3-dependent inflammation without causing broad immunosuppression (Haque et al., 2024; Perera et al., 2018; Wu et al., 2020). Additionally, structural studies and binding assays have confirmed that MCC950 interacts with the NLRP3 protein in a manner that disrupts its association with NEK7—a kinase that is indispensable for inflammasome activation—further contributing to its potent anti-inflammatory profile. This dual mechanism of inhibiting both ATP hydrolysis and interfering with NEK7 binding underscores the compound’s effectiveness in blocking NLRP3 assembly and subsequent inflammatory signaling (Coll et al., 2015).

Expected Effect in Age-Related Hearing Loss
The hypothesis underlying the evaluation of MCC950 for Age-Related Hearing Loss (ARHL) centers on the concept that chronic low-grade inflammation—referred to as “inflammaging”—is a major driver of cochlear degeneration. In the aging cochlea, the activation of the NLRP3 inflammasome has been implicated in the pathological release of IL-1β and IL-18, pro-inflammatory cytokines that contribute to the accumulation of reactive oxygen species (ROS). Elevated ROS levels, in turn, are believed to impair the function of hair cell mechanotransduction (MET) channels, which are essential for maintaining endocochlear potential and proper auditory transduction (Bazard et al., 2021; Unknown Reference, 2017). In experimental animal models, chronic activation of inflammatory pathways, as evidenced by increased levels of IL-1β, has been correlated with degraded MET channel performance and eventual hearing loss. By selectively inhibiting the NLRP3 inflammasome, MCC950 is expected to significantly reduce the maturation and release of IL-1β and IL-18. This effect would lead to a lower intracellular and extracellular concentration of these cytokines, thereby attenuating the downstream activation of NF-κB signaling and subsequent ROS production. In essence, the expected outcome in the cochlea would be a preservation of the normal function and gating properties of MET channels, maintenance of the endocochlear potential, and ultimately, a stabilization of hair cell function (Bai et al., 2021; Xing et al., 2021).

A key aspect of this therapeutic hypothesis is that NLRP3 expression has been observed in cochlear tissues during aging. Elevated markers of inflammasome activation—including ASC oligomerization, caspase-1 activation, and increased interleukin-1β levels—have been documented in aged mouse cochleae, suggesting that NLRP3-mediated inflammatory processes contribute to the decline in hair cell function (Unknown Reference, 2017). Consequently, by applying MCC950 in preclinical models of ARHL, one would expect to observe a marked reduction in these inflammatory markers along with a stabilization—or even an improvement—in auditory function. Furthermore, given its favorable pharmacokinetic properties, which include high oral bioavailability and documented blood-brain barrier penetration in rodent studies at dosing regimens typically in the range of 10–20 mg/kg, MCC950 is well-positioned for systemic administration that could reach cochlear tissues either directly or indirectly via extracellular vesicle transport pathways (Agarwal et al., 2020; Bai et al., 2021). The reduction in cytokine signaling by MCC950 would be expected to yield downstream benefits such as reduced oxidative stress, lower levels of apoptotic signaling, and preservation of cell membrane integrity of hair cells, all of which are crucial for maintaining proper mechanotransduction (Coll et al., 2015; Yan et al., 2023). In addition, by specifically targeting the NLRP3 inflammasome, MCC950 avoids the broader immunosuppressive effects that are commonly associated with corticosteroids and other anti-inflammatory agents, potentially allowing for long-term administration in a chronic condition like ARHL without compromising the overall immune function of the patient (Bai et al., 2021).

Overall Evaluation
Overall, MCC950 is a scientifically well-supported candidate for repurposing in the treatment of Age-Related Hearing Loss; its mechanism of selectively inhibiting the NLRP3 inflammasome corresponds closely with the underlying inflammatory pathways that drive cochlear degeneration during aging. One of the major strengths of MCC950 lies in its high degree of molecular selectivity—by binding to the NACHT domain of NLRP3 and preventing ATP hydrolysis, it directly disrupts the assembly of the inflammasome and halts the cascade of cytokine release that ultimately leads to tissue degradation. This precision minimizes off-target effects and reduces the risk of broad immunosuppression, which is a critical consideration in chronic therapeutic regimens (Coll et al., 2019; Perera et al., 2018). Moreover, the robust preclinical data supporting MCC950’s efficacy across various models of inflammatory pathology—ranging from neurodegenerative and autoimmune diseases to traumatic injuries—provides a compelling rationale for its evaluation in the context of ARHL, where similar inflammatory processes have been documented (Coll et al., 2015; Bai et al., 2021).

Yet, there are also challenges and weaknesses that must be addressed. First, despite the promising mechanistic rationale, direct preclinical evidence demonstrating MCC950’s efficacy in cochlear tissue or in models of ARHL is currently lacking. There are no published studies that specifically examine its effect on hair cell mechanotransduction or auditory function in vivo or in vitro; thus, the therapeutic hypothesis remains to be rigorously validated in dedicated hearing-loss models (Unknown Reference, 2017; Bazard et al., 2021). Second, previous clinical experiences with MCC950 have raised safety concerns, most notably hepatotoxicity observed in rheumatoid arthritis trials. This calls for careful dose optimization and long-term safety evaluations, especially in the context of a chronic, progressive condition such as ARHL, where prolonged dosing may be necessary (Agarwal et al., 2020; Perera et al., 2018). Third, the unique anatomical barriers associated with the inner ear pose additional challenges for effective drug delivery; although MCC950 has demonstrated favorable central nervous system penetration, its distribution specifically to cochlear tissues must be confirmed through targeted pharmacokinetic studies (Kaur et al., 2025; Keuler et al., 2022).

Additionally, while the compound’s mechanism of action is well-defined at the molecular level, the complexity of the inflammatory network in the aging cochlea may require a combinatorial therapeutic approach. Chronic inflammation in ARHL involves multiple cytokines, oxidative stress pathways, and changes in mitochondrial function, suggesting that inhibiting the NLRP3 inflammasome alone may not fully restore cochlear function. Future studies may need to assess the potential synergistic effects of MCC950 when combined with antioxidants or agents that support mitochondrial health and autophagy. Nonetheless, the targeted nature of MCC950 makes it an attractive candidate, as it can specifically modulate the deleterious aspects of the innate immune response while sparing general immune functions, a balance that is difficult to achieve with broader-spectrum anti-inflammatory drugs (Bai et al., 2021; Xing et al., 2021).

To summarize, MCC950 is a highly promising therapeutic candidate for Age-Related Hearing Loss based on its ability to selectively inhibit the NLRP3 inflammasome, thereby reducing IL-1β and IL-18 maturation and limiting the ROS production that contributes to hair cell dysfunction. Its synthetic origins, detailed structure-activity relationships, and favorable pharmacokinetic profile—including oral bioavailability and brain penetration—support its potential application in disorders driven by chronic inflammation. However, before MCC950 can be advanced to clinical trials for ARHL, several critical gaps must be addressed: preclinical studies in relevant cochlear models must be conducted to confirm its efficacy in preserving mechanotransduction channel function; its safety profile must be re-evaluated in the context of chronic administration; and effective strategies for targeting drug delivery to the inner ear must be developed. Overall, the candidate’s strengths lie in its molecular specificity, robust mechanistic rationale, and extensive validation in other inflammatory disease models, while its weaknesses include the current lack of direct evidence in ARHL and potential safety concerns that could arise during long-term treatment (Coll et al., 2015; Coll et al., 2019; Gu et al., 2025; Krishnan et al., 2019).

In conclusion, while MCC950 has not yet been directly employed for Age-Related Hearing Loss, its well-characterized inhibitory effect on NLRP3 inflammasome activation offers a scientifically compelling strategy to combat cochlear inflammaging and preserve hair cell function. The repurposing of MCC950 for ARHL is based on a strong mechanistic foundation drawn from studies in multiple inflammatory models, and its potential to reduce IL-1β-mediated oxidative stress could translate into significant clinical benefits for hearing preservation. Moving forward, further research focusing on cochlear pharmacodynamics, targeted delivery to the inner ear, and long-term safety assessments remains essential to fully validate MCC950 as a therapeutic candidate for ARHL (Agarwal et al., 2020; Bai et al., 2021; Bazard et al., 2021; Perera et al., 2018; Krishnan et al., 2019).

References
Agarwal, S., Pethani, J. P., Shah, H. A., Vyas, V., Sasane, S., Bhavsar, H., Bandyopadhyay, D., Giri, P., Viswanathan, K., Jain, M. R., & Sharma, R. (2020). Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor. Bioorganic & Medicinal Chemistry Letters, 30, Article 127571. https://doi.org/10.1016/j.bmcl.2020.127571

Bai, R., Lang, Y., Shao, J., Deng, Y., Refuhati, R., & Cui, L. (2021). The role of NLRP3 inflammasome in cerebrovascular diseases pathology and possible therapeutic targets. ASN Neuro. https://doi.org/10.1177/17590914211018100

Bazard, P., Pineros, J., Frisina, R. D., Bauer, M. A., Acosta, A. A., Paganella, L. R., Borakiewicz, D., Thivierge, M., Mannering, F. L., Zhu, X., & Ding, B. (2021). Cochlear inflammaging in relation to ion channels and mitochondrial functions. Cells, 10, Article 2761. https://doi.org/10.3390/cells10102761

Bertinaria, M., Gastaldi, S., Marini, E., & Giorgis, M. (2019). Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. Archives of Biochemistry and Biophysics, 670, 116–139. https://doi.org/10.1016/j.abb.2018.11.013

Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Latz, E., Kastner, D. L., Mills, K. H. G., Masters, S. L., Schroder, K., Cooper, M. A., & O’Neill, L. A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21, 248–255. https://doi.org/10.1038/nm.3806

Coll, R. C., Hill, J. R., Day, C. J., Zamoshnikova, A., Boucher, D., Massey, N. L., Chitty, J. L., Fraser, J. A., Jennings, M. P., Robertson, A. A. B., & Schroder, K. (2019). MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nature Chemical Biology, 15, 556–559. https://doi.org/10.1038/s41589-019-0277-7

Gu, X., Chen, C., Chen, Y., Zeng, C., Lin, Y., Guo, R., Xu, S., & Lin, C. (2025). Bioinformatics approach reveals the critical role of inflammation-related genes in age-related hearing loss. Scientific Reports. https://doi.org/10.1038/s41598-024-83428-x

Haque, I., Thapa, P., Burns, D. M., Zhou, J., Sharma, M., Sharma, R., & Singh, V. (2024). NLRP3 inflammasome inhibitors for antiepileptogenic drug discovery and development. International Journal of Molecular Sciences, 25, 6078. https://doi.org/10.3390/ijms25116078

Jiang, Y., He, L., Green, J., Blevins, H., Guo, C., Patel, S. H., Halquist, M. S., McRae, M., Venitz, J., Wang, X.-Y., & Zhang, S. (2019). Discovery of second-generation NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization. Journal of Medicinal Chemistry, 62, 9718–9731. https://doi.org/10.1021/acs.jmedchem.9b01155

Kaur, B., Biby, S., Namme, J. N., More, S., Xu, Y., & Zhang, S. (2025). Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors. Advances in Pharmacology, 102, 103–157. https://doi.org/10.1016/bs.apha.2024.10.004

Keuler, T., Ferber, D., Marleaux, M., Geyer, M., & Gütschow, M. (2022). Structure–stability relationship of NLRP3 inflammasome-inhibiting sulfonylureas. ACS Omega, 7, 8158–8162. https://doi.org/10.1021/acsomega.2c00125

Krishnan, S. M., Ling, Y. H., Huuskes, B. M., Ferens, D. M., Saini, N., Chan, C. T., Diep, H., Kett, M. M., Samuel, C. S., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Peter, K., Latz, E., Mansell, A. S., Sobey, C. G., Drummond, G. R., & Vinh, A. (2019). Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovascular Research, 115, 776–787. https://doi.org/10.1093/cvr/cvy252

Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. (2018). MCC950, a specific small-molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports. https://doi.org/10.1038/s41598-018-26775-w

Wu, D.-b., Chen, Y.-f., Sun, Y., Gao, Q., Li, H., Yang, Z., Wang, Y., Jiang, X., & Yu, B. (2020). Target of MCC950 in inhibition of NLRP3 inflammasome activation: A literature review. Inflammation, 43, 17–23. https://doi.org/10.1007/s10753-019-01098-8

Xing, Y., Fang, J., Li, Z., Li, M., Liu, C., Zhang, X., Li, Y., Mao, S., Shi, H., Su, K., Yu, D., & Shi, H. (2021). Pyroptosis accelerates spiral ganglion neuronal degeneration induced by aminoglycosides in the cochlea [Preprint]. https://doi.org/10.21203/rs.3.rs-1158387/v1

Yan, L., Huo, Y., Shi, J., Dong, Y., & Tan, H. (2023). Traditional Chinese medicine for the prevention and treatment of presbycusis. Heliyon, 9, Article e22422. https://doi.org/10.1016/j.heliyon.2023.e22422

Unknown Reference. (2017). NLRP3‐inflammasomes are triggered by age‐related hearing loss in the inner ear of mice.
